KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Short-term Investments (2020 - 2025)

Neogenomics (NEO) has disclosed Short-term Investments for 5 consecutive years, with $19.8 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Short-term Investments fell 72.73% year-over-year to $19.8 million, compared with a TTM value of $19.8 million through Dec 2024, down 72.73%, and an annual FY2024 reading of $19.8 million, down 72.73% over the prior year.
  • Short-term Investments was $19.8 million for Q4 2024 at Neogenomics, down from $25.8 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $198.6 million in Q4 2021 and bottomed at $19.8 million in Q4 2024.
  • Average Short-term Investments over 5 years is $100.6 million, with a median of $72.7 million recorded in 2023.
  • The sharpest move saw Short-term Investments skyrocketed 193.97% in 2021, then crashed 72.73% in 2024.
  • Year by year, Short-term Investments stood at $67.5 million in 2020, then skyrocketed by 193.97% to $198.6 million in 2021, then dropped by 11.96% to $174.8 million in 2022, then tumbled by 58.4% to $72.7 million in 2023, then crashed by 72.73% to $19.8 million in 2024.
  • Business Quant data shows Short-term Investments for NEO at $19.8 million in Q4 2024, $25.8 million in Q3 2024, and $72.7 million in Q4 2023.